Petrus Trust Company’s Royalty Pharma RPRX Stock Holding History

Petrus Trust Company’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,287	Closed	-$227K	–	688
2025 Q1	$227K	Buy	+7,287	New	+$231K	0.02%	497
2024 Q1	–	Sell	-13,701	Closed	-$385K	–	764
2023 Q4	$385K	Sell	13,701 -4,013	-23%	-$110K	0.04%	335
2023 Q3	$481K	Hold	17,714	–	–	0.05%	194
2023 Q2	$545K	Buy	17,714 +10,537	+147%	+$357K	0.06%	125
2023 Q1	$259K	Hold	7,177	–	–	0.03%	373
2022 Q4	$284K	Buy	+7,177	New	+$300K	0.04%	290

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIA

Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Petrus Trust Company's RPRX Position: Q2 2025 in Review

Petrus Trust Company sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 7,287 shares — an estimated $227K sold.

Petrus Trust Company first reported a position in RPRX in Q4 2022 and held it in 6 quarters. The position peaked at $545K in Q2 2023. 454 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

Petrus Trust Company reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
Petrus Trust Company sold 7,287 Royalty Pharma shares in Q2 2025, an estimated $227K.
Petrus Trust Company first reported a position in Royalty Pharma in Q4 2022 and held it in 6 quarters.
Petrus Trust Company's Royalty Pharma position peaked at $545K in Q2 2023.
454 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Petrus Trust Company's 13F filing for Q2 2025, filed 14 Aug 2025.